Skip to main content
. 2020 Jul 30;11(9):2121–2143. doi: 10.1007/s13300-020-00882-2

Fig. 5.

Fig. 5

Long-acting GLP-1RAs on MACE in patients with type 2 diabetes according to baseline BMI. HR hazard ratio, CI confidence interval, GLP-1RAs glucagon-like peptide 1 receptor agonists, BMI body mass index, MACE major adverse cardiovascular events